{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:46:57Z","timestamp":1770817617958,"version":"3.50.1"},"reference-count":10,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2019,2,14]]},"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1183\/13993003.02396-2018","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T05:54:47Z","timestamp":1552974887000},"page":"1802396","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly"],"prefix":"10.1183","volume":"53","author":[{"given":"Pei-Chun","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-Hui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ju","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Chieh","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng-Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yuan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"2024101915083602000_53.3.1802396.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00214014"},{"key":"2024101915083602000_53.3.1802396.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01470-2018"},{"key":"2024101915083602000_53.3.1802396.3","first-page":"e4126","article-title":"Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (United States)"},{"key":"2024101915083602000_53.3.1802396.4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan","volume":"111","author":"Sun","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"2024101915083602000_53.3.1802396.5","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024101915083602000_53.3.1802396.6","unstructured":"Food and Drug Administration, Ministry of Health and Welfare, Taiwan. The content of license for Priftin 150mg film-coated tablets. www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027203 Date last updated: July 28, 2017. Date last accessed: Feb 11, 2019."},{"key":"2024101915083602000_53.3.1802396.7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ323"},{"key":"2024101915083602000_53.3.1802396.8","first-page":"1374","article-title":"Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review","volume":"14","author":"Kunst","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024101915083602000_53.3.1802396.9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024101915083602000_53.3.1802396.10","first-page":"1","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"5","author":"Houben","year":"2016","journal-title":"PLoS Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02396-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:37:05Z","timestamp":1740382625000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02396-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,18]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1183\/13993003.02396-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02396-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}